Profusa, Inc., a leading developer of tissue-integrated biosensors, today announced that the National Institutes of Health has awarded it a $1.75 million grant under the Small Business Innovation Research (SBIR) program. Administered by the National Heart, Lung, and Blood Institute (NHLBI), the funding will support Fast-tracked Phase I and Phase II studies of the company's Lumee™ tissue-integrated biosensors for continuous monitoring of oxygen toward improving the clinical outcomes of patients suffering from peripheral artery disease (PAD).
Rice University synthetic biologist Jeffrey Tabor is intent upon making the gut check standard operating procedure.
Mitochondrial dysfunction plays a critical role in the development of chemical and pharmaceutical toxicity. However, current methods to evaluate mitochondrial activity still rely on traditional tests called end-point assays, which provide limited prognostic information.
Scientists of the Research Center caesar in Bonn, an Institute of the Max Planck Society, developed a new biosensor, which allows to measure nanomolar levels of the second messenger cAMP. The sensor makes it possible to study cAMP signaling with high precision, even in subcellular compartments. Using this new biosensor, the scientists of the Minerva Max Planck Research Group “Molecular Physiology“ headed by Dagmar Wachten and of the Department “Molecular Sensory Systems” headed by Benjamin Kaupp revealed how the production of cAMP is regulated in the flagella of sperm cells from mice.
Yissum Research Development Company of the Hebrew University of Jerusalem, the technology-transfer company of the Hebrew University, announced today the formation of Neteera Technologies, developer of remote sensing technology of various human biological indicators. Neteera Technologies has completed its first round of funding, raising $2.0 million from private investors.
Researchers from the University of Illinois at Urbana-Champaign have developed a highly sensitive biosensor based on a differential immuno-capture technology that can detect sub-populations of white blood cells. As part of a small, disposable biochip, the microfluidic biosensor can count CD4+/CD8+ T cells quickly and accurately for AIDS diagnosis in the field. This is a follow-up of the work earlier published by the group in Science Translational Medicine.
A portable biosensor that could show how disease is progressing in patients with Alzheimer’s could greatly improve people’s quality of life in the future, according to a new review published in Biosensors and Bioelectronics.
BIO-key International, Inc., an innovative provider of strong, interoperable biometric authentication solutions, announced that ten of the company's healthcare partners will be highlighting BIO-key solutions at the HIMSS 2016 event February 29th - March 4th, to be held at the Sands Conference Center, Las Vegas, Nevada. Over 35,000 healthcare IT professionals will attend the four day educational and networking event.
Goodix, a world leader in innovative human interface solutions for mobile devices, announced three new technologies at Mobile World Congress 2016 in Barcelona, including the world’s first Live Finger Detection™ technology to enhance security; the force-sensitive Newton Touch™ panel, and an ultra-low power heart rate sensor, which enables smart earphone with heart rate detection capability.
Royal Philips today announced that it will introduce a next-generation monitoring solution for at-risk patients in low acuity hospital settings, such as the general ward. As an industry-first, the new medical-grade biosensor enabled solution demonstrates Philips' continuing commitment to better addressing clinicians' and patients' needs through monitoring.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.